-
公开(公告)号:EP3930850A1
公开(公告)日:2022-01-05
申请号:EP20715585.4
申请日:2020-02-28
申请人: Xencor, Inc.
-
公开(公告)号:EP3620473A1
公开(公告)日:2020-03-11
申请号:EP19187150.8
申请日:2014-01-14
申请人: Xencor, Inc.
IPC分类号: C07K16/46
摘要: The invention provides novel heterodimeric proteins including heterodimeric antibodies. The present invention describes novel immunoglobulin compositions that simultaneously co-engage antigens, where both of the antigens are bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fe regions. Methods of using the novel immunoglobulin compositions, particularly for therapeutic purposes, are also described herein.
-
公开(公告)号:EP3611187A1
公开(公告)日:2020-02-19
申请号:EP19186573.2
申请日:2012-10-10
申请人: Xencor, Inc.
摘要: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
-
公开(公告)号:EP2943511B1
公开(公告)日:2019-08-07
申请号:EP14738267.5
申请日:2014-01-14
申请人: Xencor, Inc.
IPC分类号: C07K16/46
-
-
-
公开(公告)号:EP3475304A1
公开(公告)日:2019-05-01
申请号:EP17740525.5
申请日:2017-06-28
申请人: Xencor, Inc.
发明人: MOORE, Gregory , RASHID, Rumana , LEE, Sung-Hyung , FOSTER, Paul
-
公开(公告)号:EP3223907A2
公开(公告)日:2017-10-04
申请号:EP15816291.7
申请日:2015-11-25
申请人: Xencor, Inc.
发明人: MOORE, Gregory , DESJARLAIS, John , BERNETT, Matthew , CHU, Seung , RASHID, Rumana , MUCHHAL, Umesh
CPC分类号: C07K16/40 , A61K2039/505 , C07K16/18 , C07K16/2809 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/92
摘要: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
摘要翻译: 本发明涉及结合CD3和CD38的异二聚体抗体。
-
公开(公告)号:EP3936521A1
公开(公告)日:2022-01-12
申请号:EP21173787.9
申请日:2014-03-17
申请人: Xencor, Inc.
摘要: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
-
20.
-
-
-
-
-
-
-
-
-